Document:

Registration Rights Agreement

 EXHIBIT 10.2 
  
 REGISTRATION RIGHTS AGREEMENT 
  

by and among 
  
 CV THERAPEUTICS, INC., 
  
 and 
  
 THE INITIAL
PURCHASERS NAMED HEREIN 
  
 Dated May 18, 2004

  
 Registration Rights Agreement (this
“Agreement”), dated as of May 18, 2004, by and among CV Therapeutics, Inc., a Delaware corporation (together with any successor entity, the “Issuer”) and Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner &
Smith Incorporated (“Merrill Lynch”) and Citigroup Global Markets Inc., Deutsche Bank Securities Inc., First Albany Capital Inc., J.P. Morgan Securities Inc., Needham & Company, Inc., Piper Jaffray & Co. and SG Cowen & Co., LLC
(each, an “Initial Purchaser” and collectively, the “Initial Purchasers”). 
  
 Pursuant to the Purchase Agreement, dated May 12, 2004, by and among the Issuer and the Initial Purchasers (the “Purchase Agreement”),
the Initial Purchasers have agreed to purchase from the Issuer up to $125,000,000 ($150,000,000 if the Initial Purchasers’ option is exercised in full) in aggregate principal amount of 23⁄4% Senior Subordinated Convertible Notes due 2012
(the “Notes”). The Notes will be convertible into fully paid, nonassessable shares of common stock, par value $0.001 per share, of the Issuer (the “Common Stock”) on the terms, and subject to the conditions, set
forth in the Indenture (as defined herein). To induce the Initial Purchasers to purchase the Notes, the Issuer has agreed to provide the registration rights set forth in this Agreement pursuant to the Purchase Agreement. 
  
 The parties hereby agree as follows: 
  
 1. Definitions. As used in this Agreement, the following capitalized
terms shall have the following meanings: 
  
 Advice: As
defined in Section 4(c)(ii) hereof. 
  
 Agreement: As
defined in the preamble hereto. 
  
 Business Day: A day
other than a Saturday or Sunday or any federal holiday in the United States. 
  
 Commission: Securities and Exchange Commission. 
  
 Common Stock: As defined in the preamble hereto. 
  
 Damages Payment Date: Each Interest Payment Date. For purposes of this Agreement, if no Notes are outstanding, “Damages Payment Date” shall mean each May 16 and November 16. 
  
 Effectiveness Period: As defined in Section 2(a)(iii) hereof.

  
 Effectiveness Target Date: As defined in Section
2(a)(ii) hereof. 
  
 Exchange Act: Securities Exchange Act
of 1934, as amended. 
  
 Holder: A Person who owns,
beneficially or otherwise, Transfer Restricted Securities. 
  
 Indenture: The Indenture, dated as of May 18, 2004, between the Issuer and Wells Fargo Bank, N.A., as trustee, pursuant to which the Notes are to be issued, as such Indenture is amended, modified or supplemented from time to time in
accordance with the terms thereof. 
  

 Initial Purchasers: As defined in the preamble hereto. 
  
 Interest Payment Date: As defined in the Indenture. 
  
 Issuer: As defined in the preamble hereto. 
  
 Liquidated Damages: As defined in Section 3(a) hereof. 
  
 Majority of Holders: Holders holding over 50% of the aggregate
principal amount of Notes outstanding; provided, however, that, for purpose of this definition, a holder of shares of Common Stock which constitute Transfer Restricted Securities and were issued upon conversion of the Notes shall be
deemed to hold an aggregate principal amount of Notes (in addition to the aggregate principal amount of Notes held by such holder) equal to the aggregate principal amount of Notes converted by such Holder into such shares of Common Stock.

  
 Merrill Lynch: As defined in the preamble hereto.

  
 NASD: National Association of Securities Dealers, Inc.

  
 Notes: As defined in the preamble hereto. 

 
 Person: An individual, partnership, corporation, unincorporated
organization, trust, joint venture or a government or agency or political subdivision thereof. 
  
 Prospectus: The prospectus included in a Shelf Registration Statement, as amended or supplemented by any prospectus supplement and by all other amendments thereto, including post-effective amendments, and all
material incorporated by reference into such Prospectus. 
  
 Purchase Agreement: As defined in the preamble hereto. 
  
 Questionnaire Deadline: As defined in Section 2(b) hereof. 
  
 Record Holder: With respect to any Damages Payment Date, each Person who is a Holder on the record date with respect to the Interest Payment Date on which such Damages Payment Date shall occur. In the case of a
Holder of shares of Common Stock issued upon conversion of the Notes, “Record Holder” shall mean each Person who is a Holder of shares of Common Stock which constitute Transfer Restricted Securities on the May 2 or November 2 immediately
preceding the Damages Payment Date. 
  
 Registration
Default: As defined in Section 3(a) hereof. 
  
 Sale
Notice: As defined in Section 4(e) hereof. 
  
 Securities
Act: Securities Act of 1933, as amended. 
  
 Shelf Filing
Deadline: As defined in Section 2(a)(i) hereof. 
  
 Shelf
Registration Statement: As defined in Section 2(a)(i) hereof. 
  
 Suspension Period: As defined in Section 4(b)(i) hereof. 
  
 TIA: Trust Indenture Act of 1939, as in effect on the date the Indenture is qualified under the TIA. 
  
 Transfer Restricted Securities: Each Note and each share of Common Stock issued upon conversion of Notes until the earlier of: 
  
 (i) the date on which such Note or such share of Common
Stock issued upon conversion has been effectively registered under the Securities Act and disposed of in accordance with the Shelf Registration Statement; 
  

 -2- 

 (ii) the date on which such Note or such share of Common Stock issued upon conversion is
transferred in compliance with Rule 144 under the Securities Act or may be sold or transferred pursuant to Rule 144(k) under the Securities Act (or any other similar provision then in force); or 
  
 (iii) the date on which such Note or such share of Common
Stock issued upon conversion ceases to be outstanding (whether as a result of redemption, repurchase and cancellation, conversion or otherwise). 
  
 Underwritten Registration or Underwritten Offering: A registration in which securities of the Issuer are sold to an underwriter for reoffering to
the public. 
  
 2. Shelf Registration. 
  
 (a) The Issuer shall: 
  
 (i) not later than 120 days after the date hereof (the
“Shelf Filing Deadline”), cause to be filed a registration statement pursuant to Rule 415 under the Securities Act (the “Shelf Registration Statement”), which Shelf Registration Statement shall provide for resales
of all Transfer Restricted Securities held by Holders that have provided the information required pursuant to the terms of Section 2(b) hereof; 
  
 (ii) use its best efforts to cause the Shelf Registration Statement to be declared effective by the Commission as promptly as practicable,
but in no event later than 210 days after the date hereof (the “Effectiveness Target Date”); and 
  
 (iii) use its best efforts to keep the Shelf Registration Statement continuously effective, supplemented and amended as required by the
provisions of Section 4(b) hereof to the extent necessary to ensure that (A) it is available for resales by the Holders of Transfer Restricted Securities entitled to the benefit of this Agreement and (B) conforms with the requirements of this
Agreement and the Securities Act and the rules and regulations of the Commission promulgated thereunder as announced from time to time for a period (the “Effectiveness Period”) of: 
  
 (1) two years following the last date of original issuance of Notes; or

  
 (2) such shorter period that will terminate when (x) all of
the Holders of Transfer Restricted Securities are able to sell all Transfer Restricted Securities immediately without restriction pursuant to Rule 144(k) under the Securities Act or any successor rule thereto, (y) when all Transfer Restricted
Securities have ceased to be outstanding (whether as a result of redemption, repurchase and cancellation, conversion or otherwise) or (z) all Transfer Restricted Securities registered under the Shelf Registration Statement have been sold.

  
 (b) Subject to Section 2(c) below, no Holder may include any
of its Transfer Restricted Securities in the Shelf Registration Statement pursuant to this Agreement unless such Holder furnishes to the Issuer in writing, prior to or on the 20th Business Day after receipt of a request therefor (the
“Questionnaire Deadline”), such information as the Issuer may reasonably request, including the information specified in the form of questionnaire attached hereto as Exhibit A, for use in connection with the Shelf
Registration Statement or the Prospectus or preliminary Prospectus included therein and in any application to be filed with or under state securities laws. In connection with all such requests for information from Holders in addition to that set
forth in Exhibit A, the Issuer shall notify such Holders of the requirements set forth in the preceding sentence. 
  
 (c) Beginning on the date the Shelf Registration Statement is declared effective, if necessary to identify such Holder as a selling securityholder in the
Shelf Registration Statement, the Issuer shall: 
  
 (i) (1) if permitted by the SEC to file a prospectus supplement, within 10 days’ receipt of a completed questionnaire, together with such other information as the Issuer may reasonably request, file with the Commission a supplement to
the related Prospectus, or 
  

 -3- 

 (2) within 30 days’ receipt of a completed questionnaire, together with such other information as
the Issuer may reasonably request, file with the Commission a post-effective amendment to the Shelf Registration Statement or file any other document required under the Securities Act, and use its best efforts to cause such post-effective amendment
to be declared effective under the Securities Act as promptly as is practicable, but in any event by the date that is thirty days after the date such post-effective amendment is required by this clause to be filed; 
  
 (ii) provide such Holder copies of any documents filed
pursuant to Section 2(c)(i); and 
  
 (iii) notify
such Holder as promptly as practicable after (i) the filing of such prospectus supplement pursuant to Section 2(c)(i)(1), or (ii) the effectiveness under the Securities Act of any post-effective amendment filed pursuant to Section 2(c)(i)(2);

  
 provided that if such questionnaire is delivered during a
Suspension Period, the Company shall so inform the Holder delivering such questionnaire and shall take the actions set forth in clauses (i), (ii) and (iii) above upon expiration of the Suspension Period and, provided further, that in
no event shall the Issuer be required to file a post-effective amendment to the Shelf Registration Statement for the purpose of naming Holders as selling securityholders pursuant to Section 2(c)(i)(2) until the date that is 30 days after the date
the Issuer shall have received questionnaires from Holders of Transfer Restricted Securities holding an aggregate of at least $10 million aggregate principal amount of Transfer Restricted Securities and, provided further, in no event
will the Issuer be required to file a post-effective amendment to the Shelf Registration Statement more frequently than once per fiscal quarter. In connection with all such requests for information from Holders in addition to that set forth in
Exhibit A, the Issuer shall notify such Holders of the requirements set forth in the preceding sentence. 
  
 3. Liquidated Damages. 
  
 (a) If: 
  
 (i) the Shelf Registration Statement is not filed with the Commission prior to or on the Shelf Filing Deadline; 
  
 (ii) the Shelf Registration Statement has not been declared
effective by the Commission prior to or on the Effectiveness Target Date; 
  
 (iii) subject to the provisions of Section 4(b)(i) hereof, the Shelf Registration Statement is filed and declared effective but, during the Effectiveness Period, shall thereafter cease to be effective or fail to be
usable for its intended purpose without being succeeded within five Business Days by a post-effective amendment to the Shelf Registration Statement or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act that cures such failure and, in the case of a post-effective amendment, is itself immediately declared effective; 
  
 (iv) during the Effectiveness Period and after the Issuer has received a completed questionnaire, together with such other information as
the Issuer may reasonably request, the Issuer fails to: 
  
 (1)
file a supplement to the related Prospectus within 10 days’ receipt of the completed questionnaire, if the Issuer is then permitted by the SEC to file a prospectus supplement, so that the Holder delivering such questionnaire is named as a
selling securityholder in the Shelf Registration Statement and the related Prospectus, or 
  
 (2) file a post-effective amendment to the Shelf Registration Statement within 30 days’ receipt of a completed questionnaire for which the Issuer is not able to file a prospectus supplement as provided 

  

 -4- 

 
in Section 3(a)(iv)(1), so that the Holder delivering such questionnaire is named as a selling securityholder in the Shelf Registration Statement and the
related Prospectus, subject to the exceptions described in provisos in Section 2(c) above; or 
  
 (v) prior to or on the 45th, 60th or 90th day, as the case may be, of any Suspension Period, such suspension has not been terminated;

  
 (each such event referred to in foregoing clauses (i) through (v), a
“Registration Default”), the Issuer hereby agrees to pay liquidated damages (“Liquidated Damages”) with respect to the Transfer Restricted Securities from and including the day following the Registration Default to
but excluding the day on which the Registration Default has been cured: 
  
 (A) in respect of the Notes, to each holder of Notes, (x) with respect to the first 90-day period during which a Registration Default shall have occurred and be continuing, in an amount per year equal to an additional
0.25% of the principal amount of the Notes and (y) with respect to the period commencing on the 91st day following the day the Registration Default shall have occurred and be continuing, in an amount per year equal to an additional 0.50% of the
principal amount of the Notes; provided that in no event shall Liquidated Damages accrue at a rate per year exceeding 0.50% of the principal amount of the Notes; and 
  
 (B) In respect of any shares of Common Stock, to each holder of shares of Common Stock issued upon
conversion of Notes, (x) with respect to the first 90-day period in which a Registration Default shall have occurred and be continuing, in an amount per year equal to 0.25% of the principal amount of the converted Notes and (y) with respect to the
period commencing the 91st day following the day the Registration Default shall have occurred and be continuing, in an amount per year equal to 0.50% of the principal amount of the converted Notes; provided, however, that in no event
shall Liquidated Damages accrue at a rate per year exceeding 0.50% of the principal amount of the converted Notes. 
  
 (b) All accrued Liquidated Damages shall be paid in arrears to Record Holders by the Issuer on each Damages Payment Date by wire transfer of immediately
available funds or by federal funds check. Following the cure of all Registration Defaults relating to any particular Note or share of Common Stock, the accrual of Liquidated Damages with respect to such Note or share of Common Stock will cease.

  
 All obligations of the Issuer set forth in this Section 3 that
are outstanding with respect to any Transfer Restricted Security at the time such security ceases to be a Transfer Restricted Security shall survive until such time as all such obligations with respect to such Transfer Restricted Security shall have
been satisfied in full. 
  
 A Holder shall only be entitled to
Liquidated Damages pursuant to Section 3(a)(iii), Section 3(a)(iv) or Section 3(a)(v) if such Holder shall have returned a completed questionnaire to the Issuer, together with such other information as the Issuer may reasonably request. 

 
 The Liquidated Damages set forth above shall be the exclusive monetary
remedy available to the Holders for such Registration Default. 
  
 4. Registration Procedures. 
  
 (a) In connection
with the Shelf Registration Statement, the Issuer shall comply with all the provisions of Section 4(b) hereof and shall use its best efforts to effect such registration to permit the resale of the Transfer Restricted Securities in accordance with
the intended method or methods of distribution thereof, and pursuant thereto, shall as expeditiously as possible prepare and file with the Commission a Shelf Registration Statement relating to registration on any appropriate form under the
Securities Act. 
  
 (b) In connection with the Shelf Registration
Statement and any Prospectus required by this Agreement to permit the resale of Transfer Restricted Securities, the Issuer shall: 
  
 (i) Subject to any notice by the Issuer in accordance with this Section 4(b) of the existence of any fact or event of the kind described
in Section 4(b)(iii)(D), use its best efforts to keep the Shelf 

  

 -5- 

 
Registration Statement continuously effective during the Effectiveness Period. Upon the occurrence of any event that would cause the Shelf Registration
Statement or the Prospectus contained therein (A) to contain a material misstatement or omission or (B) not be effective and usable for resale of Transfer Restricted Securities during the Effectiveness Period, the Issuer shall file promptly an
appropriate amendment to the Shelf Registration Statement or a report filed with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, in the case of clause (A), correcting any such misstatement or omission, and, in the
case of either clause (A) or (B), use its best efforts to cause any such amendment to be declared effective and the Shelf Registration Statement and the related Prospectus to become usable for their intended purposes as soon as practicable
thereafter. Notwithstanding the foregoing, the Issuer may suspend the effectiveness of the Shelf Registration Statement by written notice to the Holders for a period not to exceed 45 days in any 90-day period or an aggregate of 90 days in any 360
day period (each such period, a “Suspension Period”) if, in the Issuer’s reasonable judgment, it possesses material non-public information the disclosure of which would have a material adverse effect on the business of the
Issuer (and its subsidiaries, if any, taken as a whole); provided, however, that in the event the disclosure relates to a previously undisclosed proposed or pending material business transaction, the disclosure of which would impede
the Issuer’s ability to consummate such transaction, the Issuer may extend a Suspension Period from 45 days to 60 days. 
  
 (ii) Prepare and file with the Commission such post-effective amendments to the Shelf Registration Statement as may be necessary to keep
the Shelf Registration Statement effective during the Effectiveness Period; cause the Prospectus to be supplemented by any required Prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 under the Securities Act, and to
comply fully with the applicable provisions of Rules 424 and 430A under the Securities Act in a timely manner; and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by the Shelf Registration
Statement during the applicable period in accordance with the intended method or methods of distribution by the sellers thereof set forth in the Shelf Registration Statement or Prospectus supplement. 
  
 (iii) Advise the selling Holders that have provided the
information required by Section 4(d) of this Agreement, Merrill Lynch, as representative of the Initial Purchasers, and the underwriter(s), if any, promptly (but in any event within five Business Days) and, if requested by such Persons, confirm such
advice in writing: 
  
 (A) with respect to the
Shelf Registration Statement or any post-effective amendment thereto, when the same has become effective, and when the Prospectus or any Prospectus supplement or post-effective amendment has been filed, 
  
 (B) of any request by the Commission for amendments to the
Shelf Registration Statement or amendments or supplements to the Prospectus or for additional information relating thereto, 
  
 (C) of the issuance by the Commission of any stop order suspending the effectiveness of the Shelf Registration Statement under the
Securities Act or of the suspension by any state securities commission of the qualification of the Transfer Restricted Securities for offering or sale in any jurisdiction, or the initiation of any proceeding for any of the preceding purposes, or

  
 (D) of the existence of any fact or the
happening of any event, during the Effectiveness Period, that makes any statement of a material fact made in the Shelf Registration Statement or the Prospectus, any amendment or supplement thereto, or any document incorporated by reference therein
untrue, or that requires the making of any additions to or changes in the Shelf Registration Statement or the Prospectus in order to make the statements therein not misleading. 
  
 If at any time the Commission shall issue any stop order suspending the effectiveness of the Shelf Registration Statement,
or any state securities commission or other regulatory authority shall issue an order suspending the qualification or exemption from qualification of the Transfer Restricted Securities under state securities or Blue Sky laws, the Issuer shall use
its reasonable best efforts to obtain the withdrawal or lifting of such order at the earliest possible time. 
  
 (iv) Furnish to each of the selling Holders that have provided the information required by Section 4(d) of this Agreement, Merrill Lynch,
as representative of the Initial Purchasers and each of the underwriter(s), if any, before filing with the Commission, a copy of the Shelf Registration Statement and copies of any Prospectus 

  

 -6- 

 
included therein or any amendments or supplements to the Shelf Registration Statement or Prospectus (other than documents incorporated by reference after the
initial filing of the Shelf Registration Statement), which documents will be subject to the review of such Holders, Merrill Lynch as representative of the Initial Purchasers and underwriter(s), if any, for a period of at least ten Business Days, and
the Issuer will not file any Shelf Registration Statement or Prospectus or any amendment or supplement to the Shelf Registration Statement or Prospectus (other than documents incorporated by reference) to which a selling Holder of Transfer
Restricted Securities covered by the Shelf Registration Statement, Merrill Lynch, as representative of the Initial Purchasers, or the underwriter(s), if any, shall reasonably object within five Business Days after the receipt thereof. A selling
Holder, Merrill Lynch, as representative of the Initial Purchasers, or underwriter, if any, shall be deemed to have reasonably objected to such filing if the Shelf Registration Statement, amendment, Prospectus or supplement, as applicable, as
proposed to be filed, contains a material misstatement or omission. Notwithstanding the foregoing, the Issuer shall not be required to furnish the selling Holders with any amendment or supplement to the Shelf Registration Statement or Prospectus
filed solely to reflect changes to the amount of Notes held by any particular Holder at the request of such Holder or immaterial revisions to the information contained therein. 
  
 (v) If the selling Holders propose to make an underwritten public offering of the Transfer Restricted
Securities, make available at reasonable times for inspection by one or more representatives of the selling Holders, designated in writing by a Majority of Holders whose Transfer Restricted Securities are included in the Shelf Registration
Statement, any underwriter participating in any distribution pursuant to the Shelf Registration Statement and any attorney or accountant retained by such selling Holders or any of the underwriter(s), all financial and other records, pertinent
corporate documents and properties of the Issuer as shall be reasonably necessary to enable them to exercise any applicable due diligence responsibilities, and cause the Issuer’s officers, directors, managers and employees to supply all
information reasonably requested by any such representative or representatives of the selling Holders, underwriter, attorney or accountant in connection with the Shelf Registration Statement after the filing thereof and before its effectiveness;
provided, however, that any information designated by the Issuer as confidential at the time of delivery of such information shall be kept confidential by the recipient thereof. 
  
 (vi) If requested by any selling Holders, Merrill Lynch, as
representative of the Initial Purchasers, or the underwriter(s), if any, promptly incorporate in the Shelf Registration Statement or Prospectus, pursuant to a supplement or post-effective amendment if necessary, such information as such selling
Holders, Merrill Lynch, as representative of the Initial Purchasers, and such underwriter(s), if any, may reasonably request to have included therein, including, without limitation: (1) information relating to the “Plan of Distribution” of
the Transfer Restricted Securities, (2) information with respect to the principal amount of Notes or number of shares of Common Stock being sold to such underwriter(s), (3) the purchase price being paid therefor and (4) any other terms of the
offering of the Transfer Restricted Securities to be sold in such offering; and make all required filings of such Prospectus supplement or post-effective amendment as soon as reasonably practicable after the Issuer is notified of the matters to be
incorporated in such Prospectus supplement or post-effective amendment. Notwithstanding the foregoing, following the effective date of the Shelf Registration Statement, the Issuer shall not be required to file more than one such supplement or
post-effective amendment to reflect changes in the amount of Notes held by any particular Holder at the request of such Holder in any 30-day period. 
  
 (vii) Furnish to each selling Holder, Merrill Lynch, as representative of the Initial Purchasers, and each of the underwriter(s), if any,
without charge, at least one copy of the Shelf Registration Statement, as first filed with the Commission, and of each amendment thereto (and any documents incorporated by reference therein or exhibits thereto (or exhibits incorporated in such
exhibits by reference) as such Person may request). 
  
 (viii) Deliver to each selling Holder, Merrill Lynch, as representative of the Initial Purchasers, and each of the underwriter(s), if any, without charge, as many copies of the Prospectus (including each preliminary prospectus) and any
amendment or supplement thereto as such Persons reasonably may request; subject to any notice by the Issuer in accordance with this Section 4(b) of the existence of any fact or event of the kind described in Section 4(b)(iii)(D), the Issuer hereby
consents to the use of the Prospectus and any amendment or supplement thereto by each of the selling Holders and each of the underwriter(s), if any, in connection with the offering and the sale of the Transfer Restricted Securities covered by the
Prospectus or any amendment or supplement thereto. 
  
 (ix) If an underwriting agreement is entered into and the registration is an Underwritten Registration, the Issuer shall: 
  
 (A) upon request, furnish to each selling Holder and the underwriter(s), if any, in such substance and scope as they may reasonably
request and as are customarily made by issuers to underwriters in primary underwritten offerings, upon the date of closing of any sale of Transfer Restricted Securities in an Underwritten Registration: (1) a certificate, dated the date of such
closing, signed by the Chief Financial Officer of the Issuer confirming, as of the date thereof, the matters set forth in Section 6(d) of the Purchase Agreement and such other matters as such parties may reasonably request; (2) opinions, each dated
the date of such closing, of counsel to the Issuer covering such of the matters set forth in the exhibits to the Purchase Agreement referred to in Section 6(a) and 6(b) thereof as are customarily covered in legal opinions to underwriters in
connection with primary underwritten offerings of securities; and (3) customary comfort letters, dated the date of such closing, from the Issuer’s independent certified public accountants (and from any other accountants whose report is
contained or incorporated by reference in the Shelf Registration Statement), in the customary form and covering matters of the type customarily covered in comfort letters to underwriters in connection with primary underwritten offerings of
securities; 
  

 -7- 

 (B) set forth in full in the underwriting agreement, if any, indemnification provisions
and procedures which provide rights no less protective than those set forth in Section 6 hereof with respect to all parties to be indemnified; and 
  
 (C) deliver such other documents and certificates as may be reasonably requested by such parties to evidence compliance with clause (A)
above and with any customary conditions contained in the underwriting agreement or other agreement entered into by the selling Holders pursuant to this clause (ix). 
  
 (x) Before any public offering of Transfer Restricted Securities, cooperate with the selling Holders, the
underwriter(s), if any, and their respective counsel in connection with the registration and qualification of the Transfer Restricted Securities under the securities or Blue Sky laws of such jurisdictions as the selling Holders or underwriter(s), if
any, may reasonably request and do any and all other acts or things necessary or advisable to enable the disposition in such jurisdictions of the Transfer Restricted Securities covered by the Shelf Registration Statement; provided,
however, that the Issuer shall not be required (A) to register or qualify as a foreign corporation or a dealer of securities where it is not now so qualified or to take any action that would subject it to the service of process in any
jurisdiction where it is not now so subject or (B) to subject itself to taxation in any such jurisdiction if they are not now so subject. 
  
 (xi) Cooperate with the selling Holders and the underwriter(s), if any, to facilitate the timely preparation and delivery of certificates
representing Transfer Restricted Securities to be sold and, when issued to the purchasers of Transfer Restricted Securities pursuant to the Shelf Registration Statement, not bearing any restrictive legends (unless required by applicable securities
laws); and enable such Transfer Restricted Securities to be in such denominations and registered in such names as the selling Holders or the underwriter(s), if any, may request at least two Business Days before any sale of Transfer Restricted
Securities made by the selling Holders or such underwriter(s). 
  
 (xii) Use its best efforts to cause the Transfer Restricted Securities covered by the Shelf Registration Statement to be registered with or approved by such other U.S. governmental agencies or authorities as may be
necessary to enable the seller or sellers thereof or the underwriter(s), if any, to consummate the disposition of such Transfer Restricted Securities. 
  
 (xiii) Subject to Section 4(b)(i) hereof, if any fact or event contemplated by Section 4(b)(iii)(D) hereof shall exist or have occurred,
use its reasonable best efforts to prepare a supplement or post-effective amendment to the Shelf Registration Statement or related Prospectus or any document incorporated therein by reference or file any other required document so that, as
thereafter delivered to the purchasers of Transfer Restricted Securities, the Prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading. 
  
 (xiv) Provide CUSIP
numbers for all Transfer Restricted Securities not later than the effective date of the Shelf Registration Statement and provide the Trustee under the Indenture with certificates for the Notes that are in a form eligible for deposit with The
Depository Trust Company. 
  

 -8- 

 (xv) Cooperate with respect to any filings required to be made with the NASD and in the
performance of any due diligence investigation by any underwriter that is required to be retained in accordance with the rules and regulations of the NASD. 
  
 (xvi) Otherwise use its best efforts to comply with all applicable rules and regulations of the Commission and all reporting requirements
under the rules and regulations of the Exchange Act. 
  
 (xvii) Cause the Indenture to be qualified under the TIA not later than the effective date of the Shelf Registration Statement required by this Agreement, and, in connection therewith, cooperate with the Trustee and the holders of Notes to
effect such changes to the Indenture as may be required for such Indenture to be so qualified in accordance with the terms of the TIA; and execute and use its best efforts to cause the Trustee thereunder to execute all documents that may be required
to effect such changes and all other forms and documents required to be filed with the Commission to enable such Indenture to be so qualified in a timely manner. 
  
 (xviii) Cause all Transfer Restricted Securities covered by the Shelf Registration Statement to be listed or
quoted, as the case may be, on each securities exchange or automated quotation system on which similar securities issued by the Issuer are then listed or quoted. 
  
 (xix) Make available to each Holder upon written request each document filed with the Commission pursuant to
the requirements of Section 13 and Section 15 of the Exchange Act after the effective date of the Shelf Registration Statement. 
  
 (xx) If requested by the underwriters, make appropriate officers of the Issuer available to the underwriters for meetings with prospective
purchasers of the Transfer Restricted Securities and prepare and present to potential investors customary “road show” material in a manner consistent with new issuances of other securities similar to the Transfer Restricted Securities.

  
 (xxi) Use its best efforts to obtain a waiver
from each person who would otherwise have the right to have securities of the Issuer (other than Transfer Restricted Securities) registered on the Shelf Registration Statement required by this Agreement. To the extent the Issuer does not receive
such waivers, it will use its best efforts to obtain the consent of such persons from whom waivers are not obtained to file a separate registration statement with respect to all such other registrable securities, rather than include them in the
Shelf Registration Statement and, upon receipt of such consent, to register such registrable securities in accordance therewith. 
  
 (c) Each Holder agrees by acquisition of a Transfer Restricted Security that, upon receipt of any notice from the Issuer of the existence of any fact of
the kind described in Section 4(b)(iii)(D) hereof, such Holder will, and will use its reasonable best efforts to cause any underwriter(s) in an Underwritten Offering to, forthwith discontinue disposition of Transfer Restricted Securities pursuant to
the Shelf Registration Statement until: 
  
 (i)
such Holder has received copies of the supplemented or amended Prospectus contemplated by Section 4(b)(xiii) hereof; or 
  
 (ii) such Holder is advised in writing (the “Advice”) by the Issuer that the use of the Prospectus may be resumed, and
has received copies of any additional or supplemental filings that are incorporated by reference in the Prospectus. If so directed by the Issuer, each Holder will deliver to the Issuer (at the Issuer’s expense) all copies, other than permanent
file copies then in such Holder’s possession, of the Prospectus covering such Transfer Restricted Securities that was current at the time of receipt of such notice of suspension. 
  
 (d) Each Holder who intends to be named as a selling Holder in the Shelf Registration Statement shall furnish to the Issuer
in writing, prior to or on the 20th Business Day after receipt of a request therefor as set forth in a questionnaire, such information regarding such Holder and the proposed distribution by such Holder of its Transfer Restricted Securities as the
Issuer may reasonably request for use in connection with the Shelf Registration Statement or Prospectus or preliminary Prospectus included therein. (The form of the questionnaire is attached hereto as Exhibit A.) Holders that do not complete
the questionnaire and deliver it to the Issuer shall not be named as selling securityholders in the Prospectus or preliminary Prospectus included in the Shelf Registration Statement and therefore shall not be 

  

 -9- 

 
permitted to sell any Transfer Restricted Securities pursuant to the Shelf Registration Statement. Each Holder who intends to be named as a selling Holder in
the Shelf Registration Statement shall promptly furnish to the Issuer in writing such other information as the Issuer may from time to time reasonably request in writing. Each Holder as to which the Shelf Registration Statement is being effected
agrees to furnish promptly to the Issuer all information required to be disclosed in order to make information previously furnished to the Issuer by such Holder not materially misleading. 
  
 (e) Upon the effectiveness of the Shelf Registration Statement, each Holder shall notify the Issuer at least three Business
Days prior to any intended distribution of Transfer Restricted Securities pursuant to the Shelf Registration Statement (a “Sale Notice”), which Sale Notice shall be effective for five Business Days. Each Holder of this Security, by
accepting the same, agrees to hold any communication by the Issuer in response to a Sale Notice in confidence. 
  
 5. Registration Expenses. 
  
 (a) All expenses incident to the Issuer’s performance of or compliance with this Agreement shall be borne by the Issuer regardless of whether a Shelf
Registration Statement becomes effective, including, without limitation: 
  
 (i) all registration and filing fees and expenses (including filings made by any Initial Purchasers, Holders or underwriters with the NASD); 
  
 (ii) all fees and expenses of compliance with federal securities and state Blue Sky or securities laws;

  
 (iii) all expenses of printing (including
printing of Prospectuses and certificates for the Common Stock to be issued upon conversion of the Notes), messenger and delivery services and telephone; 
  
 (iv) all fees and disbursements of counsel to the Issuer and, subject to Section 5(b) below, the Holders of Transfer Restricted
Securities; 
  
 (v) all application and filing
fees in connection with listing (or authorizing for quotation) the Common Stock on a national securities exchange or automated quotation system pursuant to the requirements hereof; and 
  
 (vi) all fees and disbursements of independent certified public accountants of the Issuer (including the
expenses of any special audit and comfort letters required by or incident to such performance). 
  
 The Issuer shall bear its internal expenses (including, without limitation, all salaries and expenses of their officers and employees performing legal, accounting or other duties), the expenses of any annual audit and
the fees and expenses of any Person, including special experts, retained by the Issuer. 
  
 (b) In connection with the review of the Shelf Registration Statement and other documents referred to in this Agreement, the Issuer shall, against a reasonably detailed invoice therefor, reimburse Merrill Lynch, on
behalf of the Initial Purchasers, and the Holders of Transfer Restricted Securities being registered pursuant to the Shelf Registration Statement, for the reasonable fees and disbursements of not more than one counsel, which shall be Wilson Sonsini
Goodrich & Rosati, Professional Corporation, or such other counsel as may be chosen by a Majority of Holders for whose benefit the Shelf Registration Statement is being prepared. 
  
 6. Indemnification and Contribution. 
  
 (a) The Issuer agrees to indemnify and hold harmless each Initial Purchaser (and each of their directors, officers and
employees), each Holder whose securities are included in a Shelf Registration Statement (and each of their directors, officers and employees), each Person who participates as an underwriter (any such Person being an “Underwriter”)
and each Person, if any, who controls any Initial Purchaser, Holder or Underwriter within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act as follows: 
  
 (i) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue statement of a material fact contained in such Shelf Registration Statement (or any amendment thereto), including all documents incorporated therein by reference,
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact
contained in any Prospectus (or any amendment or supplement thereto) or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading; 
  

 -10- 

 (ii) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or
omission, or any such alleged untrue statement or omission; provided, however that (subject to Section 6(d) below) any such settlement is effected with the written consent of the Issuer; and 
  
 (iii) against any and all expense whatsoever, as incurred
(including the fees and disbursements of counsel chosen by any indemnified party), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced
or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under subparagraph (i) or (ii) above; 
  
 provided, however, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information furnished to the Issuer by the Initial
Purchasers, such Holder or such Underwriter expressly for use in a Shelf Registration Statement (or any amendment thereto) or any Prospectus (or any amendment or supplement thereto). 
  
 (b) Each Holder whose securities are included in a Shelf Registration Statement, severally but not jointly, agrees to
indemnify and hold harmless the Issuer (and its directors, officers and employees), the Initial Purchasers (and each of their directors, officers and employees), each Underwriter (and each of their directors, officers and employees) and the other
selling Holders (and each of their directors, officers and employees) and each Person, if any, who controls the Issuer, the Initial Purchasers, any Underwriter or any other selling Holder within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 6(a) hereof, as incurred, but only with respect to untrue statements or omissions, or alleged untrue
statements or omissions, made in such Shelf Registration Statement (or any amendment thereto) or any Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with written information with respect to such Holder
furnished to the Issuer by such Holder expressly for use in such Shelf Registration Statement (or any amendment thereto) or such Prospectus (or any amendment or supplement thereto); provided, however, that no such Holder shall be
liable for any claims hereunder in excess of the amount of net proceeds received by such Holder from the sale of Transfer Restricted Securities pursuant to such Shelf Registration Statement. 
  
 (c) Each indemnified party shall give notice as promptly as reasonably
practicable to each indemnifying party of any action or proceeding commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party shall not relieve such indemnifying party from any
liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. An indemnifying party may
participate at its own expense in the defense of such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. In no event
shall the indemnifying party or parties be liable for the fees and expenses of more than one counsel (in addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but
similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry
of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could be sought under this
Section 6 (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability 

  

 -11- 

 
arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a
failure to act by or on behalf of any indemnified party. 
  
 (d)
If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated
by Section 6(a)(ii) effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms
of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement; provided,
however, that an indemnifying party shall not be liable for any such settlement if such indemnifying party (1) reimburses such indemnified party in accordance with such request for the amount of such fees and expenses of such counsel as the
indemnifying party believes in good faith to be reasonable and (2) provides written notice to the indemnified party and the indemnifying party disputes in good faith the reasonable ness of the unpaid balance of such fees and expenses. 
  
 (e) If the indemnification provided for in this Section 6 is for any reason
unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses,
liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Issuer from the offering and sale of the Transfer Restricted
Securities on the one hand and a Holder with respect to the sale by the Holder of the Transfer Restricted Securities on the other hand; or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the indemnifying party or parties on the one hand and the indemnified party or parties on the other hand in connection with the statements
or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations. 
  
 The relative benefits received by the Issuer on the one hand and a Holder on the other hand with respect to such offering and such sale shall be deemed to
be in the same proportion as the total net proceeds from the offering of the Notes purchased under the Purchase Agreement (before deducting expenses) received by the Issuer, as set forth in the Offering Memorandum dated May 12, 2004 relating to the
Notes on the one hand bear to the total net proceeds received by such Holder with respect to its sale of Transfer Restricted Securities on the other. The relative fault of the indemnifying party or parties on the one hand and the indemnified party
or parties on the other hand shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by
the indemnifying party or parties on the one hand or the indemnified party or parties on the other hand and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

  
 The parties hereto agree that it would not be just and
equitable if contribution pursuant to this Section 6 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this Section 6. The aggregate amount of
losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 6 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged
omission. 
  
 Notwithstanding the provisions of this Section 6, no
Holder shall be required to contribute any amount in excess of the amount by which the total price at which the Transfer Restricted Securities purchased by it were resold exceeds the amount of any damages which such Holder has otherwise been
required to pay by reason of any untrue or alleged untrue statement or omission or alleged omission. The Holders’ obligations to contribute as provided in this Section 6(e) are several and not joint. No Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 For purposes of this Section 6, each Person, if any, who controls an Initial Purchaser, a Holder or an Underwriter within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same rights to contribution as such Initial Purchaser, such Holder or such Underwriter, and each director of the Issuer, 

  

 -12- 

 
and each Person, if any, who controls the Issuer within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act shall have the same
rights to contribution as the Issuer. 
  
 7. Rule 144A. In
the event the Issuer is not subject to Section 13 or 15(d) of the Exchange Act, the Issuer hereby agrees with each Holder, for so long as any Transfer Restricted Securities remain outstanding, to make available to any Holder or beneficial owner of
Transfer Restricted Securities in connection with any sale thereof and any prospective purchaser of such Transfer Restricted Securities from such Holder or beneficial owner, the information required by Rule 144A(d)(4) under the Securities Act in
order to permit resales of such Transfer Restricted Securities pursuant to Rule 144A. 
  
 8. Participation in Underwritten Registrations. No Holder may participate in any Underwritten Registration hereunder unless such Holder: 
  
 (i) agrees to sell such Holder’s Transfer Restricted Securities on the basis provided in any
underwriting arrangements approved by the Persons entitled hereunder to approve such arrangements, and 
  
 (ii) completes and executes all reasonable questionnaires, powers of attorney, indemnities, underwriting agreements, lock-up letters and
other documents required under the terms of such underwriting arrangements. 
  
 9. Selection of Underwriters. The Holders of Transfer Restricted Securities covered by the Shelf Registration Statement who desire to do so may sell such Transfer Restricted Securities in an Underwritten
Offering. In any such Underwritten Offering, the investment banker or investment bankers and manager or managers that will administer the offering will be selected by a Majority of Holders whose Transfer Restricted Securities are included in such
offering; provided, that such investment bankers and managers must be reasonably satisfactory to the Issuer. 
  
 10. Miscellaneous. 
  
 (a) Remedies. The Issuer acknowledges and agrees that any failure by the Issuer to comply with its obligations under Section 2 hereof may result in
material irreparable injury to the Initial Purchasers or the Holders for which there is no adequate remedy at law, that it will not be possible to measure damages for such injuries precisely and that, in the event of any such failure, the Initial
Purchasers or any Holder may obtain such relief as may be required to specifically enforce the Issuer’s obligations under Section 2 hereof. The Issuer further agrees to waive the defense in any action for specific performance that a remedy at
law would be adequate. 
  
 (b) Adjustments Affecting Transfer
Restricted Securities. The Issuer shall not, directly or indirectly, take any action with respect to the Transfer Restricted Securities as a class that would adversely affect the ability of the Holders to include such Transfer Restricted
Securities in a registration undertaken pursuant to this Agreement. 
  
 (c) No Inconsistent Agreements. The Issuer will not, on or after the date of this Agreement, enter into any agreement with respect to its securities that is inconsistent with the rights granted to the Holders in this Agreement or
otherwise conflicts with the provisions hereof. In addition, the Issuer shall not, on or after the date hereof, grant to any of its security holders (other than the holders of Transfer Restricted Securities in such capacity) the right to include any
of its securities in the Shelf Registration Statement provided for in this Agreement other than the Transfer Restricted Securities. Except as disclosed in the Offering Memorandum dated May 12, 2004 relating to the Notes, the Issuer has not
previously entered into any agreement (which has not expired or been terminated) granting any registration rights with respect to its securities to any Person which rights conflict with the provisions hereof. 
  
 (d) Amendments and Waivers. This Agreement may not be amended,
modified or supplemented, and waivers or consents to or departures from the provisions hereof may not be given, unless the Issuer has obtained the written consent of a Majority of Holders. 
  
 (e) Notices. All notices and other communications provided for or
permitted hereunder shall be made in writing by hand-delivery, first-class mail (registered or certified, return receipt requested), telex, telecopier, or air courier guaranteeing overnight delivery: 
  

 -13- 

 (i) if to a Holder, at the address set forth on the records of the registrar under the
Indenture or the transfer agent of the Common Stock, as the case may be; and 
  
 (ii) if to the Issuer: 
  
 CV
Therapeutics, Inc. 
 3172 Porter Drive 
 Palo Alto, California 94304 
 Attention: General Counsel 
  
 With a copy (which shall not constitute notice) to: 
  
 Latham & Watkins LLP. 
 135 Commonwealth Drive 
 Menlo Park, California 94025 
 Attention: Alan C. Mendelson, Esq. 
  
 All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five Business Days after being
deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt acknowledged, if telecopied; and on the next Business Day, if timely delivered to an air courier guaranteeing overnight delivery. 
  
 (f) Successors and Assigns. This Agreement shall inure to the benefit
of and be binding upon the successors and assigns of each of the parties, including without limitation and without the need for an express assignment, subsequent Holders of Transfer Restricted Securities; provided, however, that (i)
this Agreement shall not inure to the benefit of or be binding upon a successor or assign of a Holder unless and to the extent such successor or assign acquired Transfer Restricted Securities from such Holder and (ii) nothing contained herein shall
be deemed to permit any assignment, transfer or other disposition of Transfer Restricted Securities in violation of the terms of the Purchase Agreement or the Indenture. If any transferee of any Holder shall acquire Transfer Restricted Securities,
in any manner, whether by operation of law or otherwise, such Transfer Restricted Securities shall be held subject to all of the terms of this Agreement, and by taking and holding such Transfer Restricted Securities such person shall be conclusively
deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement. 
  
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 
  
 (h) Securities Held by the Issuer or Their Affiliates. Whenever the consent or approval of Holders of a specified percentage of Transfer Restricted
Securities is required hereunder, Transfer Restricted Securities held by the Issuer or its “affiliates” (as such term is defined in Rule 405 under the Securities Act) shall not be counted in determining whether such consent or approval was
given by the Holders of such required percentage. 
  
 (i)
Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
  
 (j) Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of New York. 
  
 (k) Severability. If any one or more of the provisions contained
herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be
affected or impaired thereby. 
  
 (l) Entire Agreement.
This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein.
There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein with respect to the registration rights granted by the Issuer with respect to the Transfer Restricted Securities. This Agreement
supersedes all prior agreements and understandings between the parties with respect to such subject matter. 
  

 -14- 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

					
	CV THERAPEUTICS, INC.
		
	By:	 	/s/    LOUIS G. LANGE        
	 	 	 Name:
	 	 Louis G. Lange, M.D., Ph.D.

	 	 	 Title:
	 	 Chairman and Chief Executive Officer

  
 Accepted as of the date

 first set forth above: 
  
 MERRILL LYNCH & CO. 
 MERRILL LYNCH, PIERCE, FENNER & SMITH

 INCORPORATED 
  
 CITIGROUP GLOBAL MARKETS INC. 
 DEUTSCHE BANK SECURITIES INC. 
 FIRST ALBANY CAPITAL INC. 
 J.P. MORGAN SECURITIES INC. 
 NEEDHAM & COMPANY, INC. 
 PIPER JAFFRAY & CO. 
 SG COWEN & CO., LLC 
  

			
	 By: MERRILL LYNCH, PIERCE, FENNER & SMITH

	INCORPORATED
		
	By:	 	 
	 	 	 Authorized Signatory

		
	 	 	 For themselves and the other Initial Purchasers

  

 -15- 

 Exhibit A 
  
 CV THERAPEUTICS, INC. 
 INSTRUCTION TO DTC PARTICIPANTS 
 , 2004 
  
 URGENT - IMMEDIATE ATTENTION REQUESTED 
  
 DEADLINE FOR RESPONSE: [            ], 2004

  
 The Depository Trust Company (“DTC”) has
identified you as a DTC Participant through which beneficial interests in the CV Therapeutics, Inc. (the “Issuer”) 23⁄4% Senior Subordinated Convertible Notes due May 16, 2012 (the “Securities”) are held.

  
 The Issuer is in the process of registering the Securities
under the Securities Act of 1933, as amended, for resale by the beneficial owners thereof. In order to have their Securities included in the registration statement, beneficial owners must complete and return the enclosed Notice of Registration
Statement and Selling Securityholder Questionnaire. 
  
 It is
important that beneficial owners of the Securities receive a copy of the enclosed materials as soon as possible as their rights to have the Securities included in the registration statement depend upon their returning the Notice and
Questionnaire by [            ], 2004. Please forward a copy of the enclosed documents to each beneficial owner that holds interests in the Securities through you. If you require more
copies of the enclosed materials or have any questions pertaining to this matter, please contact Tricia Borga Suvari, CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304. 
  

 CV THERAPEUTICS, INC. 
  
 Selling Securityholder Notice and Questionnaire 
  
 , 2004 
  
 The undersigned beneficial holder of 23⁄4% Senior Subordinated Convertible Notes due May 16, 2012 (the “Notes”) of CV Therapeutics, Inc. (the
“Company”) or common stock, par value $0.001 per share issuable upon conversion of the Notes (the “Common Stock” and together with the Notes, the “Transfer Restricted Securities”), of the Company understands that the
Company has filed or intends to file with the Securities and Exchange Commission a registration statement (the “Shelf Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended, of the
Transfer Restricted Securities in accordance with the terms of the Registration Rights Agreement, dated as of May 18, 2004 (the “Registration Rights Agreement”), among the Company and the Initial Purchaser named therein. A copy of the
Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 
  
 Each beneficial owner of Transfer Restricted Securities is entitled to the
benefits of the Registration Rights Agreement. In order to sell or otherwise dispose of any Transfer Restricted Securities pursuant to the Shelf Registration Statement, a beneficial owner of Transfer Restricted Securities generally will be required
to be named as a selling securityholder in the related prospectus, deliver a prospectus to purchasers of Transfer Restricted Securities and be bound by those provisions of the Registration Rights Agreement applicable to such beneficial owner
(including certain indemnification provisions). Beneficial owners who complete and deliver this Notice and Questionnaire at least five business days prior to the effectiveness of the Shelf Registration Statement will be named as selling
securityholders in the related prospectus at the time of effectiveness (the “Effective Time”). After the Effective Time, any beneficial owner of Notes wishing to include its Transfer Restricted Securities must deliver to the Company a
properly completed and signed Notice and Questionnaire and the Company will include it in a prospectus supplement within ten business days, or if a post-effective amendment to the Shelf Registration Statement is required, in a post-effective
amendment within 30 business days, provided, however, that in no event shall the Company be required to file a post-effective amendment to the Shelf Registration Statement for the purpose of naming holders as selling securityholders
until the Company shall have received Notice and Questionnaires from holders of Transfer Restricted Securities holding an aggregate of at least $10 million aggregate principal amount of Transfer Restricted Securities and, provided
further, that in no event shall the Company be required to file a post-effective amendment to the Shelf Registration Statement more than once in any fiscal quarter. 
  
 Certain legal consequences arise from being named as a selling securityholder in the Shelf Registration Statement and the
related prospectus. Accordingly, holders and beneficial owners of Transfer Restricted Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the
Shelf Registration Statement and the related prospectus. 
  
 NOTICE 
  
 The undersigned beneficial owner (the
“Selling Securityholder”) of Transfer Restricted Securities hereby gives notice to the Company of its intention to sell or otherwise dispose of Transfer Restricted Securities beneficially owned by it and listed below in Item 3 (unless
otherwise specified under Item 3) pursuant to the Shelf Registration Statement. The undersigned, by signing and returning this Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and
Questionnaire and the Registration Rights Agreement. 
  
 Upon any
sale of Transfer Restricted Securities pursuant to the Shelf Registration Statement, the Selling Securityholder will be required to deliver to the Company and Trustee the Notice of Transfer set forth as Exhibit B to the Registration Rights
Agreement. 
  
 The Selling Securityholder hereby provides the
following information to the Company and represents and warrants that such information is accurate and complete: 
  

 QUESTIONNAIRE 
  

							
	(1)	  	Name of Selling Securityholder, Registered Holder and DTC Participant:
			
	 	  	(a)	  	Full Legal Name of Selling Securityholder:
				
	 	  	 	  	 	  	 
			
	 	  	(b)	  	Full Legal Name of Registered Holder (if not the same as in (a) above) of Transfer Restricted Securities Listed in Item (3) below:
				
	 	  	 	  	 	  	 
			
	 	  	(c)	  	Full Legal Name of DTC Participant (if applicable and if not the same as (b) above) Through Which Transfer Restricted Securities Listed in Item (3) below are
Held:
				
	 	  	 	  	 	  	 

							
		
	(2)	  	Address for Notices to Selling Securityholder:
	 	  	 	  	 
	 	  	 	  	 
	 	  	 	  	 
	 	  	Telephone:	  	 
	 	  	Fax:	  	 
	 	  	Contact Person:	  	 

							
		
	(3)	  	Beneficial Ownership of Securities:
		
	 	  	Except as set forth below in this Item (3), the undersigned does not beneficially own any Transfer Restricted Securities.
			
	 	  	(a)	  	Principal amount at maturity of Transfer Restricted Securities beneficially owned:
				
	 	  	 	  	 	  	 
			
	 	  	 	  	CUSIP No(s). of such Transfer Restricted Securities:
				
	 	  	 	  	 	  	 
			
	 	  	 	  	Number of shares of Common Stock (if any) issued upon conversion of such Transfer Restricted Securities:
				
	 	  	 	  	 	  	 
			
	 	  	(b)	  	Principal amount at maturity of securities of the Company other than Transfer Restricted Securities beneficially owned:
				
	 	  	 	  	 	  	 
			
	 	  	 	  	CUSIP No(s). of such other
securities:                                      
                                        
                                        
                                        
     
				
	 	  	 	  	 	  	 
			
	 	  	 	  	Number of Shares (if any) issued upon conversion of such other securities:
				
	 	  	 	  	 	  	 
			
	 	  	(c)	  	Principal amount at maturity of Transfer Restricted Securities which the undersigned wishes to be included in the Shelf Registration Statement:
				
	 	  	 	  	 	  	 
			
	 	  	 	  	CUSIP No(s). of such Transfer Restricted Securities to be included in the Shelf Registration Statement:
				
	 	  	 	  	 	  	 

  

							
				
	 	  	 	 	 	 	Number of Shares (if any) issued upon conversion, repurchase or redemption of Transfer Restricted Securities which are to be included in the Shelf Registration Statement:
				
	 	  	 	 	 	 	                                      
                                        
                                        
                                        
                                        
                                      
 
		
	(4)	  	Beneficial Ownership of Other Securities of the Company:
		
	 	  	 Except as set forth in this Item (4), the undersigned Selling Securityholder is not the beneficial or registered owner of any
shares of Common Stock or any other securities of the Company, other than the Transfer Restricted Securities and securities of the Company listed above in Item (3).
  
 State any exceptions here:

		
	(5)	  	Relationships with the Company:
		
	 	  	 Except as set forth below, neither the Selling Securityholder nor any of its affiliates, officers, directors or principal equity
holders (5% or more) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
  
 State any exceptions here:

		
	(6)	  	 Beneficial Ownership by Natural Persons:
  
 If the Selling Securityholder is an entity, does any natural person have voting or investment power over the Transfer Restricted
 Securities held by the Selling Securityholder?
  
 Yes  ̈ No  ̈
  
 If so,
please state that person’s or persons’ name(s):

		
	 	  	                                      
                                        
                                        
                                        
                                        
                                        
         
		
	(7)	  	 Short Positions in the Company’s Common Stock:
  
 Except as set forth below, the undersigned Selling Securityholder does not have any open short positions in the Company’s
 Common Stock:

		
	 	  	                                      
                                        
                                        
                                        
                                        
                                        
         
		
	 	  	By signing below, the undersigned hereby confirms to the Company that it has reviewed and understood Telephone Interpretation A. 65 of the Division of Corporation Finance’s
Manual of Publicly Available Telephone Interpretations (July 1997), which provides as follows:
		
	 	  	An issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet effective. One of the selling shareholders wanted to do a short sale
of common stock “against the box” and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made before the registration statement becomes effective, because the
shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were effectively sold prior to the effective date.
		
	(8)	  	Registered Broker-Dealers:
			
	 	  	(a)	 	Is the Selling Securityholder:
				
	 	  	 	 	(i)	 	a broker-dealer: Yes  ̈ No  ̈

  

							
	 	  	 	  	(ii)	  	an affiliate of a broker-dealer: Yes  ̈ No  ̈

							
			
	 	  	(b)	  	If the Selling Securityholder is an affiliate of a broker/dealer, indicate the nature of the affiliation.
				
	 	  	 	  	 	  	 
			
	 	  	(c)	  	Except as set forth below, if the undersigned is an affiliate of a broker-dealer, the undersigned represents and warrants that it bought the Transfer Restricted
Securities in the ordinary course of business and at the time of the purchase had no agreements or understandings, directly or indirectly, with any person to distribute the Transfer Restricted Securities.
				
	 	  	 	  	 	  	 
			
	 	  	(d)	  	If the undersigned is a registered broker-dealer, please indicate whether the undersigned purchased its Transfer Restricted Securities for investment or acquired
them as transaction-based compensation for investment banking or similar services.
				
	 	  	 	  	 	  	 
				
	 	  	 	  	 	  	 NOTE: The Company is required to identify you as an underwriter in the Shelf Registration Statement and related Prospectus if
either:
  
 (i)     the undersigned is a registered broker-dealer and received its Transfer Restricted Securities other than as transaction-based compensation, or
  
 (ii)    the undersigned is an
affiliate of a broker-dealer who did not buy Transfer Restricted Securities in the ordinary course of business and at the time of your purchase had an agreement or understanding, directly or indirectly, with any person to distribute the Transfer
Restricted Securities.

			
	 	  	(e)	  	Except as set forth below, if the undersigned is a registered broker-dealer, the undersigned does not plan to make a market in the Transfer Restricted Securities. If the
undersigned plans to make a market in the Transfer Restricted Securities, please indicate whether you plan to use the prospectus relating to the Transfer Restricted Securities as a market-making prospectus.
				
	 	  	 	  	 	  	 
		
	(9)	  	 Plan of Distribution:
  
 Except as set forth below, the undersigned Selling Securityholder intends to distribute the Transfer Restricted Securities listed above in Item (3) only as follows (if
at all): Such Transfer Restricted Securities may be sold from time to time directly by the undersigned Selling Securityholder or, alternatively, through underwriters, broker-dealers or agents. Such Transfer Restricted Securities may be sold in one
or more transactions at fixed prices, at prevailing market prices at the time of sale, at varying prices determined at the time of sale, or at negotiated prices. Such sales may be effected in transactions (which may involve crosses or block
transactions) (i) on any national securities exchange or quotation service on which the Registered Securities may be listed or quoted at the time of sale, (ii) in the over-the-counter market, (iii) in transactions otherwise than on such exchanges or
services or in the over-the-counter market, or (iv) through the writing of options. In connection with sales of the Transfer Restricted Securities in the course of hedging the positions they assume. The Selling Securityholder may also sell Transfer
Restricted Securities short and deliver Transfer Restricted Securities to close out such short positions, or loan or pledge Transfer Restricted Securities to broker-dealers that in turn may sell such securities.
  
 State any exceptions here:

  

 Note: In no event may such method(s) of distribution take the form of an underwritten offering of the
Transfer Restricted Securities without the prior agreement of the Company. 
  

	 	(10)	Status at Time of Effectiveness of the Shelf Registration Statement: If you are returning this Notice and Questionnaire after the Effective Time: 

  
 At the Effective Time or at the time a post-effective amendment became
effective, the Notes referred to by you in Section 3(a), above, were beneficially owned by a person named as a selling securityholder in the Shelf Registration Statement and identified as being beneficially owned by such selling securityholder in
the Shelf Registration Statement at the time the Shelf Registration Statement became effective or such post-effective amendment became effective; or 
  
 You are unable to determine (because of insufficient information or otherwise) whether the foregoing circumstances were met or they were not met.

  
 Please Note: If you are returning this Notice and
Questionnaire after the Effective Time, unless you qualify for and check the first box, you can only be added to the Shelf Registration Statement by means of a post-effective amendment. The Company is only required to file a post-effective amendment
to the Shelf Registration Statement for the purpose of naming holders as Selling Securityholders once the Company has received Notice and Questionnaires from such Selling Securityholders holding an aggregate of at least $10 million aggregate
principal amount of Transfer Restricted Securities, provided that the Company will not be required to file a post-effective amendment more than once in any fiscal quarter. 
  
 By signing below, the Selling Securityholder acknowledges that it understands its obligation to comply, and agrees that it
will comply, with the provisions of the Exchange Act and the rules to regulations thereunder, particularly Regulation M. 
  
 In the event that the Selling Securityholder transfers all or any portion of the Transfer Restricted Securities listed in Item (3) above after the date on
which such information is provided to the Company, the Selling Securityholder agrees to notify in writing the Company and any transferee(s) at the time of the transfer of its rights and obligations under this Notice and Questionnaire and the
Registration Rights Agreement. 
  
 By signing below, the Selling
Securityholder consents to the disclosure of the information contained herein in its answers to Items (1) through (6) above and the inclusion of such information in the Shelf Registration Statement and related prospectus. The Selling Securityholder
understands that such information will be relied upon by the Company in connection with the preparation of the Shelf Registration Statement and related prospectus. 
  
 In accordance with the Selling Securityholder’s obligation under Section 2(b) of the Registration Rights Agreement to
provide such information as may be required by law for inclusion in the Shelf Registration Statement, the Selling Securityholder agrees to promptly notify the Company in writing of any inaccuracies or changes in the information provided herein which
may occur subsequent to the date hereof at any time while the Shelf Registration Statement remains in effect. All notices hereunder and pursuant to the Registration Rights Agreement shall be made in writing, by hand-delivery, first class mail, or
air courier guaranteeing overnight delivery as follows: 
  

			
	To the Company:	  	 
	 	  	 CV Therapeutics, Inc.
 3172 Porter Drive
 Palo Alto, California 94304
 Telephone: (650) 384-8500
 Facsimile: (650) 858-0388
 Attention: General Counsel

  

 -4- 

			
	With a copy (which shall not constitute notice) to:	  	 
	 	  	 Latham & Watkins LLP
 135 Commonwealth
Drive
 Menlo Park, California 94025
 Telephone: (650)
463-4693
 Facsimile: (650) 463-2600
 Attention: Alan C.
Mendelson

  
 Once this Notice and
Questionnaire is executed by the Selling Securityholder and received by the Company’s counsel, the terms of this Notice and Questionnaire, and the representations and warranties contained herein, shall be binding on, shall inure to the benefit
of and shall be enforceable by the respective successors, heirs, personal representatives, and assigns of the Company and the Selling Securityholder (with respect to the Transfer Restricted Securities beneficially owned by such Selling
Securityholder and listed in Item (3) above). This Agreement shall be governed in all respects by the laws of the State of New York. 
  
 IN WITNESS WHEREOF, the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by
its duly authorized agent. 
  
 Dated:
                             
  

	
	 
	Selling Securityholder
	 (Print/type full legal name of beneficial owner of Transfer Restricted Securities)

  

			
		
	By:	 	 
	 	 	 Name:

	 	 	 Title:

  
 PLEASE RETURN THE COMPLETED AND
EXECUTED NOTICE AND QUESTIONNAIRE FOR RECEIPT ON OR BEFORE             , 2004 TO THE COMPANY’S COUNSEL AT: 
  

			
	 	  	 Latham & Watkins LLP
 135 Commonwealth
Drive
 Menlo Park, California 94025
 Telephone: (650)
463-4693
 Facsimile: (650) 463-2600
 Attention: Anne
Shonk

  

 -5- 

 Exhibit B 
  
 NOTICE OF TRANSFER PURSUANT TO REGISTRATION STATEMENT 
  
 Wells Fargo Bank, N.A. 
 Sixth & Marquette

 MAC N9303 120 
 Minneapolis, Minnesota 55479 
 Attention: Corporate Trust Services 
  

	 	Re:	CV Therapeutics, Inc. 

	 	  	23⁄4% Senior Subordinated Convertible Notes 

	 	  	due May 16, 2012 (the “Notes”) 

  
 Dear Sirs: 
  
 Please be advised that
                                 has transferred
$             aggregate principal amount at maturity (subject to upward adjustment in the event of an upward interest adjustment) of the above-referenced Notes pursuant to an
effective Registration Statement on Form                      (File No.
333-            ) filed by the Issuer. 
  
 We hereby certify that the prospectus delivery requirements, if any, of the Security Act of 1933, as amended, have been satisfied and that the above-named
beneficial owner of the Notes is named as a “Selling Holder” in the Prospectus dated                     , or in supplements
thereto, and that the aggregate principal amount of the Notes transferred are the Notes listed in such Prospectus opposite such owner’s name. 
  

			
	 	 	Very truly yours,
		
	 	 	 
	 	 	 (Name)

		
	By:	 	 
	 	 	 (Authorized Signature)Pledge and Escrow Agreement

 Exhibit 10.3 

  
 PLEDGE AND ESCROW AGREEMENT 
  
 by and among 
  
 CV THERAPEUTICS, INC., 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION, 
 as Trustee, 
  
 and 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION, 
 as Escrow Agent 
  
 Dated as of May 18, 2004 
  

 PLEDGE AND ESCROW AGREEMENT 
  
 THIS PLEDGE AND ESCROW AGREEMENT (this “Agreement”), dated as of May 18, 2004, is by and among CV
Therapeutics, Inc. (the “Company”), Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”), and Wells Fargo Bank, National Association, in its capacity as escrow
agent (the “Escrow Agent”). 
  
 RECITALS

  
 The Company and the Trustee have entered into an
Indenture, dated as of May 18, 2004 (the “Indenture”), pursuant to which the Company will issue up to $150,000,000 in aggregate principal amount of its 23⁄4% Senior Subordinated Convertible Notes due 2012 (the
“Notes”). 
  
 The Company desires to establish an
escrow account with the Escrow Agent into which an amount equal to 8.25% of the aggregate principal amount of the Notes originally issued from time to time under the Indenture will be, simultaneously with the original issuance of the Notes,
deposited by the Company to be held and distributed in accordance with the terms and conditions set forth herein, and the Escrow Agent is willing to establish such an account and to accept such funds in accordance with the terms hereinafter set
forth. 
  
 Capitalized terms used but not defined herein shall
have the meanings assigned to such terms in the Indenture. 
  
 AGREEMENT 
  
 NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 Section 1. Establishment of Escrow Account. The Escrow Agent shall establish on the date hereof and maintain in the Trustee’s
name a “securities account” (within the meaning of Article 8 of the Uniform Commercial Code of the State of New York as in effect from time to time (the “New York UCC”)) (the “Escrow Account”) to which
there shall be immediately credited and held amounts received by the Escrow Agent from the Company in accordance with Section 3 hereof. The funds credited to the Escrow Account shall be applied and disbursed only as provided herein. The Escrow Agent
shall segregate the funds credited to the Escrow Account from its other funds held as an agent or in trust. The Escrow Agent shall treat all property held by it in the Escrow Account as “financial assets” (as defined in Section 8-102(a)(9)
of the New York UCC) in accordance with Section 8-501 (or successor section) of the New York UCC. 
  
 Section 2. Deposit to the Escrow Account; Investments. 
  
 (a) Concurrently with the execution and delivery of this Agreement, the Company shall deliver to the Escrow Agent for
deposit in the Escrow Account an amount equal to 8.25% of the aggregate principal amount of the Notes originally issued under the Indenture on the date hereof (the “Initial Escrow Funds”). Concurrently with the original issuance of
any additional Notes under the Indenture after the date hereof in connection with the exercise of the Initial Purchasers’ option to purchase additional Notes pursuant to Section 2(b) of the Purchase 

  

 
Agreement, the Company shall deliver to the Escrow Agent for deposit in the Escrow Account an additional amount equal to 8.25% of the aggregate principal
amount of such additional Notes (the “Additional Escrow Funds” and, together with the Initial Escrow Funds, the “Escrow Funds”). All amounts to be deposited with the Escrow Agent shall be transferred by wire
transfer of immediately available funds to the following account: 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION 
 ABA No.: 121000248 
 Account No.: 0001038377 
 Account Name:
Corporate Trust Clearing Account 
 FFC: Wells Fargo as Trustee for CVT 2.75% Holders, 
           Account No. 16112301 
 Attention: Joseph Taffe 
  
 (b) Promptly following the deposit of any funds into the Escrow Account, the Escrow Agent shall invest such funds in the name of the Trustee in Government
Securities. For purposes of this Agreement, “Government Securities” shall mean (i) noncallable direct obligations of, or noncallable obligations the payment of principal of and interest on which are unconditionally guaranteed by,
the United States of America; (ii) noncallable bonds, debentures or notes issued by Federal National Mortgage Association, Government National Mortgage Association, Federal Farm Credit Banks, Federal Land Banks, Federal Home Loan Banks, Farmers Home
Administration, Federal Home Loan Mortgage Corporation or any of their successors or any other comparable federal agency hereafter created to the extent that said obligations are unconditionally guaranteed by the United States of America; and (iii)
holdings in any mutual fund or similar investment vehicle that holds only securities of the type set forth in (i) or (ii) above. Promptly following the deposit of any funds into the Escrow Account, the Company shall provide written instructions to
the Escrow Agent as to the specific Government Securities in which funds are to be invested. All such amounts shall remain so invested until the close of business on the Business Day prior to any withdrawal by the Escrow Agent pursuant to Section 4
hereof. All Government Securities from time to time credited to the Escrow Account constituting “security entitlements” as defined in Section 8-102(a)(17) of the New York UCC shall be held in the name of the Trustee and in no event shall
the Company be or be deemed to be the “entitlement holder” (as such term is defined in as defined in Section 8-102(a)(7) of the New York UCC) with respect thereto. 
  
 Section 3. Security Interest. 
  
 (a) Pledge and Assignment. The Company hereby irrevocably pledges, assigns, grants, hypothecates and sets over to the
Trustee, for the equal and ratable benefit of the Holders of the Notes, a first priority continuing security interest in all of the Company’s right, title and interest in and to all of the following whether now owned or existing or hereafter
acquired or created (collectively, the “Collateral”): 
  
 (i) all funds from time to time held in the Escrow Account, including, without limitation, the Escrow Funds and all certificates and instruments, if any, from time to time, representing or evidencing the Escrow Account or the Escrow Funds;

  

 2 

 (ii) all investments of funds in the Escrow Account, which all shall constitute Government Securities,
and whether held by or registered in the name of the Escrow Agent and all certificates and instruments, if any, from time to time representing or evidencing any such Government Securities; 
  
 (iii) all promissory notes, certificates of deposit, deposit accounts,
checks and other instruments evidencing such Government Securities from time to time hereafter delivered to or otherwise possessed by the Escrow Agent, for or on behalf of the Company, in substitution for or in addition to any or all of the then
existing Collateral; 
  
 (iv) all interest, dividends, cash,
instruments, securities and other property from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of the then existing Collateral; and 
  
 (v) all proceeds of the foregoing including, without limitation, all cash proceeds and all non-cash proceeds thereof.

  
 The Trustee hereby appoints the Escrow Agent to act as the
Trustee’s agent, on behalf of the Holders of the Notes, for purposes of perfecting the foregoing pledge, assignment and security interest in the Collateral, and the Escrow Agent hereby accepts such appointment. For so long as the foregoing
pledge, assignment and security interest remains in effect, the Escrow Agent hereby waives any right of setoff or banker’s lien that it, in its individual capacity or in its capacity as an agent for Persons other than the Trustee and the
Holders of the Notes, may have with respect to any or all of the Collateral. 
  
 (b) Secured Obligations. This Agreement secures the due and punctual payment and performance of all obligations of the Company, whether now or hereafter existing, under the Notes, the Indenture and this
Agreement, including, without limitation, interest and premium, if any, accrued on the Notes after the commencement of a bankruptcy, reorganization or similar proceeding involving the Company to the extent permitted by applicable law (collectively,
the “Secured Obligations”). 
  
 (c) Delivery
of Collateral. All certificates or instruments, if any, representing or evidencing all or any portion of the Collateral shall be held by the Escrow Agent on behalf of the Trustee pursuant hereto and shall be in suitable form for transfer by
delivery, or shall be accompanied by duly executed instruments of transfer or assignments in blank, all in form and substance reasonably satisfactory to the Escrow Agent, and all in form and substance sufficient to convey a valid security interest
in such Collateral to the Trustee. All securities in uncertificated or book-entry form and all security entitlements, if any, in each case representing or evidencing the Collateral shall be registered in the name of the Escrow Agent (or any of its
nominees) as the registered owner thereof, by book-entry or as otherwise appropriate so as to properly identify the interest of the Escrow Agent therein. In addition, the Escrow Agent shall have the right, at any time following the occurrence of an
Event of Default, to transfer to or to register in the name of the Escrow Agent or any of its nominees any or all other Collateral. Except as otherwise provided herein, all Collateral shall be deposited and held in the Escrow Account. The Escrow
Agent shall have the right at any time to exchange certificates or instruments representing or evidencing all or 

  

 3 

 
any portion of the Collateral for certificates or instruments of smaller or larger denominations in the same aggregate amount. 
  
 (d) Maintaining the Escrow Account. So long as this Agreement is in
full force and effect: 
  
 (i) subject to the other terms and
conditions of this Agreement, all Collateral held by the Escrow Agent pursuant to this Agreement shall be held in the Escrow Account, which shall be subject to the exclusive dominion and control of the Trustee for the benefit of the Trustee and the
equal and ratable benefit of the Holders of the Notes; 
  
 (ii)
the Escrow Account and all Collateral from time to time therein shall remain segregated from all other funds or other property otherwise held by the Trustee or the Escrow Agent, as applicable; 
  
 (iii) all amounts (including, without limitation, any Escrow Funds or
interest on or other proceeds of the Escrow Funds or any Government Securities held in the Escrow Account) shall remain on deposit in the Escrow Account until withdrawn in accordance with this Agreement; and 
  
 (iv) the Escrow Agent shall take all steps necessary to ensure that the
Trustee is the holder or entitlement holder (as the case may be) of all of the Collateral and that either the Trustee for the equal and ratable benefit of the Holders of the Notes or, to the extent required by applicable law, the Escrow Agent, for
the benefit of the Trustee and the equal and ratable benefit of the Holders of the Notes, is the holder or entitlement holder of all Government Securities and other uncertificated securities on the books of the applicable Federal Reserve Bank or
other applicable securities intermediary. 
  
 (e) Further
Assurances. Prior to, contemporaneously herewith, and at any time and from time to time hereafter, the Company shall, at the Company’s expense, execute and deliver to the Trustee or its designee such other instruments and documents, and
take all further action as the Trustee deems reasonably necessary or advisable or may reasonably request to confirm or perfect the security interest of the Trustee granted or purported to be granted hereby or to enable the Trustee to exercise and
enforce its rights and remedies hereunder with respect to any Collateral, and the Company shall take all necessary action to preserve and protect the security interest created hereby as a first priority, perfected lien and encumbrance upon the
Collateral. 
  
 (f) Transfers and Other Liens. The Company
agrees that it shall not (i) sell, assign (by operation of law or otherwise) or otherwise dispose of, or grant any option with respect to, any of the Collateral or (ii) create or permit to exist any Lien upon or with respect to any of the
Collateral, except for the security interest under Section 3 of this Agreement. 
  

 4 

 Section 4. Distributions from Escrow Account. Funds (or Government Securities that
are scheduled to mature or that can be liquidated on or before the date of the applicable Scheduled Interest Payment) on deposit in the Escrow Account shall be withdrawn by the Escrow Agent and transferred only in accordance with this Section 4:

  
 (a) Event of Default. 
  
 (i) For so long as an Event of Default has occurred and is continuing under
the Indenture, no amounts shall be disbursed from the Escrow Account, except as provided in clause (ii) below. 
  
 (ii) If (A) any Event of Default has occurred and is continuing under Section 4.1 of the Indenture, (B) any other Event of Default has occurred and is
continuing that results in the acceleration of the payment of principal, interest, premium, if any, and Liquidated Damages, if any, pursuant to the terms of the Indenture, or (C) any material breach or violation of any representation, warranty or
agreement contained in this Agreement has occurred: 
  
 (I) The
Trustee may, without notice to the Company except as required by applicable law and at any time or from time to time, direct the Escrow Agent to liquidate all Collateral and transfer all proceeds thereof to the Paying Agent to apply such funds in
accordance with Section 4.2 of the Indenture. 
  
 (II) The
Trustee (and/or the Escrow Agent on its behalf) may also, in addition to the other rights and remedies provided for herein, exercise in respect of the Collateral all the rights and remedies of a secured party upon default under the New York UCC, and
may also, without notice except as specified below, sell the Collateral or any part thereof in one or more parcels at public or private sales, at any of the Trustee’s or the Escrow Agent’s offices or elsewhere, for cash, on credit or for
future delivery, and upon such other terms as the Trustee may deem commercially reasonable. The Company agrees that, to the extent notice of sale shall be required by law, at least twenty (20) days’ notice to the Company of the time and place
of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Trustee and the Escrow Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been
given. The Trustee and/or the Escrow Agent on its behalf may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which
it was so adjourned. 
  
 (III) Any cash held by the Escrow Agent
as Collateral and all net cash proceeds received by the Trustee or the Escrow Agent in respect of any sale or liquidation of, collection from, or other realization upon all or any part of the Collateral may, in the discretion of the Trustee, be held
by the Trustee or the Escrow Agent as collateral for, and then or at any time thereafter be applied (after payment of any costs and expenses incurred in connection with any sale, liquidation or disposition of or realization upon the Collateral and
the payment of any amounts payable to the Trustee or the Escrow Agent) in whole or in part by the Trustee or the Escrow Agent for the equal and ratable benefit of the Holders of the Notes against all or any part of the Secured Obligations in such
order as the Trustee shall elect. Any surplus of such cash or cash proceeds held by the Trustee or the Escrow Agent and remaining after payment in full of all the Secured Obligations and the costs and expenses incurred by and amounts payable to the
Trustee or the Escrow Agent hereunder or under the Indenture shall be paid over to the Company. 
  

 5 

 (b) Scheduled Interest Payments. Pursuant to the Notes and Section 2.1 of the Indenture, the
Company is obligated to make payments of interest on the Notes on each of November 16, 2004, May 16, 2005, November 16, 2005, May 16, 2006, November 16, 2006 and May 16, 2007 (each, a “Scheduled Interest Payment”). The Scheduled
Interest Payments due on the Notes may be made, at the election of the Company, from (1) amounts held in the Escrow Account in accordance with the procedures set forth in subsection (i) below or (2) other sources of funds available to the Company,
as anticipated in subsection (ii) below, or from any combination of (1) and (2) above; provided, however, that nothing herein shall be construed as limiting the Company’s obligation to make all interest payments due on the Notes at the
times and in the amounts required by the Notes, which obligation shall be absolute and unconditional. 
  
 (i) Payment of Interest. If the Company elects to cause a Scheduled Interest Payment to be made using funds held in the Escrow Account, then, not
later than five (5) Business Days prior to the date of the applicable Scheduled Interest Payment, the Company shall direct the Escrow Agent in writing to transfer from the Escrow Account to the Paying Agent funds (or Government Securities that are
scheduled to mature or that can be liquidated on or before the date of the applicable Scheduled Interest Payment) necessary to provide for payment in full (or, if the Company intends to make a portion of such interest payment with funds or
Government Securities in the Escrow Account and the remainder of such interest payment with funds other than those in the Escrow Account, such portion) of the next Scheduled Interest Payment on the Notes. At or prior to 1:00 p.m., New York City
time, on the day that is no later than one (1) Business Day following receipt of such notice, the Escrow Agent shall transfer such funds (or such Government Securities, as applicable) to the Paying Agent as set forth in paragraph (e)(ii) hereof, and
shall notify the Company in writing that it has made such transfer to the Paying Agent. If the Company does not intend to utilize the funds (or Government Securities) in the Escrow Account to make any such Scheduled Interest Payment in full, then
the Company shall make the Scheduled Interest Payment from Company Funds (as defined in Section 4(b)(ii) below). 
  
 (ii) Release of Funds to the Company Due to Direct Payment of Interest by the Company. If the Company makes any Scheduled Interest Payment or a
portion of any Scheduled Interest Payment from a source of funds other than the Escrow Account (“Company Funds”), the Company may, after payment in full of such Scheduled Interest Payment and upon at least five (5) Business Days
prior notice, direct the Escrow Agent, so long as no Event of Default has occurred and is continuing, to release to the Company (or at the direction of the Company, to release to a designated third party) an amount of funds or Government Securities
from the Escrow Account, the sum of the cumulative interest payments on and aggregate principal amount of which is less than or equal to the amount of Company Funds so expended in making the Scheduled Interest Payment. Upon receipt of such notice,
the Escrow Agent shall pay over or transfer to the Company the requested amount. 
  
 (c) Investment Income. Subject to the provisions of Sections 3 and 4(a) above, all investment income earned on amounts on deposit in the Escrow Account is the personal property of the Company. Subject to the
provisions of Section 9(b) hereof, promptly following receipt of any investment income earned on amounts on deposit in the Escrow Account, the Escrow Agent shall transfer such funds to the Company pursuant to Section 4(e)(i) hereof. 
  

 6 

 (d) Excess Escrow Funds. If, in the course of funding the Escrow Account pursuant to Section 2(a)
hereof, the Company either elects or is required to deposit in the Escrow Account funds in an amount greater than that which is required to fund the payment of the Scheduled Interest Payments (in order to permit the Escrow Agent to purchase an
amount of Government Securities equal to or greater than that which is required to fund the payment of the Scheduled Interest Payments or otherwise) (any such excess amounts being hereinafter referred to as “Excess Escrow Funds”),
the Company may, upon at least five (5) Business Days prior written notice, direct the Escrow Agent, so long as no Event of Default has occurred and is continuing, to release to the Company (or at the direction of the Company, to release to a
designated third party) an amount of funds or Government Securities from the Escrow Account, the sum of the cumulative interest payments on and aggregate principal amount of which is less than or equal to the amount of the Excess Escrow Funds. Upon
receipt of such notice, the Escrow Agent shall pay over or transfer to the Company the requested amount. 
  
 (e) Wire Transfer. 
  
 (i) All funds distributed from the Escrow Account to the Company shall be transferred by wire transfer of immediately available funds to the following
account: 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION 

ABA No.: 121000248 
 Account No.:
0000840245 
 Wells Fargo Client Account No.: 10126300 
 Account Name: CV Therapeutics, Inc. 
  
 (ii) All funds (or Government Securities that are scheduled to mature or that can be liquidated on or before the date of the applicable Scheduled Interest Payment) distributed from the Escrow Account to the Paying Agent for payment on the
Notes shall be transferred by an account-to-account transfer of immediately available funds to the following account: 
  
 WELLS FARGO BANK, NATIONAL ASSOCIATION 
 ABA
No.: 121000248 
 Account No.: 0001038377 
 Account Name: Corporate Trust Clearing Account 
 FFC: CV Therapeutics 2.75% Conv Notes due 2012, 

         Account No. 16112300 
 Attention: Joseph Taffe 
  
 (f) Written Instructions; Certificates. The Company shall, upon request by the Escrow Agent, execute and deliver to the Escrow Agent such
additional written instructions and certificates hereunder as may be reasonably required by the Escrow Agent to give effect to this Section 4. 
  
 Section 5. Termination of Security Interest. Upon payment in full of the Scheduled Interest Payments, the security interest evidenced
by this Agreement in any Collateral remaining in the Escrow Account shall automatically terminate and be of no further force and 

  

 7 

 
effect. Furthermore, upon the release of any Collateral from the Escrow Account in accordance with the terms of this Agreement, whether upon release of such
Collateral to Holders of Notes as payment of interest on the Notes, to the Company pursuant to Sections 4(b)(ii) or 4(c) or otherwise, the security interest evidenced by this Agreement in such Collateral so released shall automatically terminate and
be of no further force and effect. The Escrow Agent shall, upon request by the Company, execute and deliver to the Company such additional written instructions and certificates hereunder as may be reasonably required by the Company to give effect to
this Section 5. 
  
 Section 6.
Attorneys-in-Fact. The Company hereby irrevocably appoints each of the Trustee and the Escrow Agent as the Company’s attorney-in-fact, coupled with an interest, with full authority in the place and stead of the Company and in
the name of the Company or otherwise, from time to time in the Trustee’s or the Escrow Agent’s discretion to take any action and to execute any instrument that the Trustee or the Escrow Agent may deem necessary or advisable to accomplish
the purposes of this Agreement, including, without limitation, to receive, endorse and collect all instruments made payable to the Company representing any interest payment, dividend or other distribution in respect of the Collateral or any part
thereof and to give full discharge for the same, and the expenses of the Trustee and the Escrow Agent incurred in connection therewith shall be payable by the Company. 
  
 Section 7. Trustee or Escrow Agent May Perform. Without limiting the authority granted under Section 6
hereof, if the Company fails to perform any agreement contained herein, the Trustee or the Escrow Agent may, but shall not be obligated to, itself perform, or cause performance of, such agreement, and the expenses of the Trustee or the Escrow Agent
incurred in connection therewith shall be payable by the Company and shall be secured by the Collateral. 
  
 Section 8. Representations, Warranties and Agreements. 
  
 (a) The Company represents, warrants and agrees that: 
  
 (i) The execution, delivery and performance by the Company of this Agreement is within its corporate power, has been duly
authorized by all necessary corporate action of the Company, and does not contravene, or constitute a default under, any provision of applicable law or regulation or of any agreement, judgment, injunction, order, decree or other instrument binding
upon the Company (except as would not, individually or in the aggregate, have a Material Adverse Effect (as defined in the Purchase Agreement)), or of the certificate of incorporation or bylaws of the Company or result in the creation or imposition
of any Lien on any assets of the Company other than the Lien contemplated hereby. 
  
 (ii) The Company has full corporate power and authority to enter into this Agreement and has the right to vote, pledge and grant a security interest in the Collateral as provided by this Agreement. 
  
 (iii) This Agreement has been duly executed and delivered by the Company and
constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. 
  

 8 

 (iv) Upon the execution and delivery of this Agreement by the parties hereto and the delivery to the
Escrow Agent of the Collateral, the pledge of the Collateral pursuant to this Agreement creates a valid and perfected first priority security interest in the Collateral, securing the payment of the Secured Obligations for the benefit of the Trustee,
the Escrow Agent and the Holders of the Notes, enforceable as such against all creditors of the Company and any persons purporting to purchase any of the Collateral from each of them. 
  
 (v) No consent of any other person and no consent, authorization, approval, or other action by, and no notice to or filing
with, any governmental authority or regulatory body is required either (i) for the pledge by the Company of the Collateral pursuant to this Agreement or for the execution, delivery or performance of this Agreement by each of them or (ii) for the
exercise by the Trustee or the Escrow Agent of the remedies in respect of the Collateral pursuant to this Agreement. 
  
 (vi) No litigation, investigation or proceeding of or before any arbitrator or governmental authority is pending or, to the best knowledge of the
Company, threatened by or against the Company or against any of its properties or revenues with respect to this Agreement or any of the transactions contemplated hereby. 
  
 (vii) The pledge of the Collateral pursuant to this Agreement is not prohibited by any applicable law or governmental
regulation, release, interpretation or opinion of the Board of Governors of the Federal Reserve System or other regulatory agency (including, without limitation, Regulations T, U and X of the Board of Governors of the Federal Reserve System).

  
 (viii) All information set forth herein relating to the
Collateral is accurate and complete in all material respects. 
  
 (b) The Escrow Agent represents, warrants and agrees that: 
  
 (i) The Escrow Agent is a “bank” within the meaning of Section 9-102(a)(8) of the New York UCC. 
  
 (ii) The Escrow Agent is a “securities intermediary” within the meaning of Section 8-102(a)(14) of the New York UCC. 
  
 (c) The Trustee represents, warrants and agrees that it is an
“entitlement holder” within the meaning of Section 8-102(a)(7) of the New York UCC. 
  
 Section 9. Fees and Expenses of Escrow Agent. 
  
 (a) The Company agrees to pay the Escrow Agent its agreed-upon compensation for its services as Escrow Agent hereunder promptly upon request therefor, and to reimburse the Escrow Agent for all reasonable and
documented expenses of or disbursements incurred by the Escrow Agent in the performance of its duties hereunder, including the reasonable fees, expenses and disbursements of legal counsel to the Escrow Agent. 
  

 9 

 (b) The Escrow Agent shall have a lien upon any investment income on deposit in the Escrow Account solely
for any costs, expenses and fees that may arise hereunder and may retain that portion of the investment income in the Escrow Account equal to such unpaid amounts, until all such costs, expenses and fees have been paid. 
  
 Section 10. Rights, Duties and Immunities of Escrow
Agent. Acceptance by the Escrow Agent of its duties under this Agreement is subject to the following terms and conditions, which all parties to this Agreement hereby agree shall govern and control the rights, duties and immunities of the
Escrow Agent: 
  
 (a) The duties and obligations of the Escrow
Agent shall be determined solely by the express provisions of this Agreement and the Escrow Agent shall not be liable except for the performance of such duties and obligations as are specifically set out in this Agreement. The Escrow Agent shall not
be required to inquire as to the performance or observation of any obligation, term or condition under any agreement or arrangement between the Company and the Trustee. The Escrow Agent is not a party to, and is not bound by, any agreement or other
document out of which this Agreement may arise. The Escrow Agent shall be under no liability to any party hereto by reason of any failure on the part of any party hereto (other than the Escrow Agent) or any maker, guarantor, endorser or other
signatory of any document or any other person to perform such person’s obligations under any such document. The Escrow Agent shall not be bound by any waiver, modification, termination or rescission of this Agreement or any of the terms hereof,
unless evidenced by a writing delivered to the Escrow Agent signed by the proper party or parties and, if the duties or rights of the Escrow Agent are affected, unless it shall give its prior written consent thereto. This Agreement shall not be
deemed to create a fiduciary relationship between the parties hereto under state or federal law. 
  
 (b) The Escrow Agent shall not be responsible in any manner for the validity or sufficiency of this Agreement or of any property delivered hereunder, or
for the value or collectibility of any note, check or other instrument, if any, so delivered, or for any representations made or obligations assumed by any party other than the Escrow Agent. Nothing herein contained shall be deemed to obligate the
Escrow Agent to deliver any cash, instruments, documents or any other property referred to herein, unless the same shall have first been received by the Escrow Agent pursuant to this Agreement. 
  
 (c) The Company shall reimburse and indemnify the Escrow Agent for, and hold
it harmless against, any loss, liability or expense, including but not limited to reasonable legal counsel fees, incurred without bad faith, gross negligence or willful misconduct on the part of the Escrow Agent, arising out of or in conjunction
with its acceptance of, or the performance of its duties and obligations under, this Agreement, as well as the costs and expenses of defending against any claim or liability arising out of or relating to this Agreement. 
  
 (d) The Escrow Agent shall be fully protected in acting on and relying upon
any written notice, direction, request, waiver, consent, receipt or other paper or document which the Escrow Agent in good faith believes to have been signed and presented by the Company. 
  
 (e) The Escrow Agent shall not be liable for any error of judgment, or for any act done or step taken or omitted by it in
good faith or for any mistake in act or law, or for 

  

 10 

 
anything which it may do or refrain from doing in connection herewith, except its own gross negligence or willful misconduct. 
  
 (f) The Escrow Agent may seek the advice of legal counsel in the event of any
dispute or question as to the construction of any of the provisions of this Agreement or its duties hereunder, and except for its own bad faith, gross negligence or willful misconduct it shall incur no liability and shall be fully protected in
respect of any action taken, omitted or suffered by it in good faith in accordance with the advice or opinion of such counsel. 
  
 (g) The parties hereto agree that if the Escrow Agent is notified by the Trustee, the Company or the Holders of the Notes of any dispute with respect to
the payment, ownership or right of possession of the Escrow Account, the Escrow Agent is authorized and directed to retain in its possession, without liability to anyone, except for its bad faith, willful misconduct or gross negligence, all or any
part of the Escrow Account until such dispute shall have been settled either by mutual agreement by the parties concerned or by the final order, decree or judgment of a court or other tribunal of competent jurisdiction in the United States of
America, and a notice executed by the parties to the dispute or their authorized representatives shall have been delivered to the Escrow Agent setting forth the resolution of the dispute. The Escrow Agent shall be under no duty whatsoever to
institute, defend or partake in such proceedings. 
  
 (h) The
agreements set forth in this Section 10 shall survive the resignation or removal of the Escrow Agent, the termination of this Agreement and the payment of all amounts hereunder. 
  
 Section 11. Resignation or Removal of Escrow Agent. 
  
 (a) The Escrow Agent shall have the right to resign upon 30 days’ prior
written notice to the Company and the Trustee. The Company shall have the right to remove the Escrow Agent upon 30 days’ prior written notice to the Escrow Agent and the Trustee. In the event of such resignation or removal, the Company shall
appoint a successor escrow agent hereunder by delivering to the Escrow Agent a written notice of such appointment. Upon receipt of such notice, the Escrow Agent shall deliver to the designated successor escrow agent all money and other property held
hereunder and shall thereupon be released and discharged from any and all further responsibilities whatsoever under this Agreement; provided, however, that the Escrow Agent shall not be deprived of its compensation earned prior to such time.

  
 (b) If no successor escrow agent shall have been designated by
the date specified in the Escrow Agent’s notice, all obligations of the Escrow Agent hereunder shall nevertheless cease and terminate. The Escrow Agent’s sole responsibility thereafter shall be to keep safely all property then held by it
and to deliver the same to a person designated by the other parties hereto or in accordance with the direction of a final order or judgment of a court of competent jurisdiction. 
  
 Section 12. Miscellaneous. 
  
 (a) Waiver. No waiver of any provision of this Agreement nor consent to any departure by any party therefrom shall in
any event be effective unless the same shall be in 

  

 11 

 
writing and signed by each of the non-breaching parties and then such waiver or consent shall be effective only in the specific instance and for the specific
purpose for which given. 
  
 (b) Severability. If, for any
reason whatsoever, any one or more of the provisions of this Agreement shall be held or deemed to be inoperative, unenforceable or invalid in a particular case or in all cases, such circumstances shall not have the effect of rendering any of the
other provisions of this Agreement inoperative, unenforceable or invalid, and the inoperative, unenforceable or invalid provision shall be construed as if it were written so as to effectuate, to the maximum extent possible, the parties’ intent.

  
 (c) Binding Effect. This Agreement shall inure to and
be binding upon the parties and their respective successors and permitted assigns; provided, however, that the Company may not assign its rights or obligations hereunder without the express prior written consent of the Trustee. 
  
 (d) Choice of Law. The existence, validity, construction, operation
and effect of any and all terms and provisions of this Agreement shall be determined in accordance with and governed by the internal laws of the State of New York including, without limitation the New York UCC, without giving effect to the conflicts
of law principles of such State. The securities intermediary’s jurisdiction for purposes of Section 8-110 of the New York UCC shall be the State of New York. 
  
 (e) Entire Agreement. This Agreement, the Purchase Agreement, the Notes and the Indenture contain the entire
agreement among the parties with respect to the subject matter hereof and supersede any and all prior agreements, understandings and commitments with respect thereto, whether oral or written; provided, however, that this Agreement is executed
and accepted by the Trustee and the Escrow Agent subject to all terms and conditions of its acceptance of the trust under the Indenture, as fully as if said terms and conditions were set forth at length herein. 
  
 (f) Amendments. This Agreement may be amended only by a writing signed
by duly authorized representatives of all parties. The Trustee and the Escrow Agent may execute an amendment to this Agreement only if the requisite consent of each of the Holders of the Notes required by Article VII of the Indenture has been
obtained, unless no such consent is required by such Section 7.1 of the Indenture. 
  

 12 

 (g) Notices. All notices, requests, instructions, orders and other communications required or
permitted to be given or made under this Agreement to any party hereto shall be delivered in writing by hand delivery or overnight delivery, or shall be delivered by facsimile or telephonically with machine confirmation of full delivery not more
than 24 hours following such facsimile or telephonic notice. A notice given in accordance with the preceding sentence shall be deemed to have been duly given upon the sending thereof. Notices should be addressed as follows: 
  
 To the Company: 
  
 CV Therapeutics, Inc. 
 3172 Porter Drive 
 Palo Alto, California 94304 
 Attention: General Counsel 
 Facsimile number: (650) 858-0388 
 Telephone number: (650) 384-8611 
  
 With a copy (which shall not constitute notice) to: 
  
 Latham & Watkins LLP 
 135 Commonwealth Drive 
 Menlo Park, California 94025 
 Attention: Alan C. Mendelson, Esq. 
 Facsimile number: (650) 463-4639 
 Telephone number: (650) 328-4600 
  
 To the Trustee or the Escrow Agent: 
  
 Wells Fargo Bank, National Association 
 Corporate Trust Services 
 MAC N9303-110 
 Sixth and Marquette Avenue 
 Minneapolis, Minnesota 55479 
 Attention: Michael T. Lechner 
 Facsimile number: (612) 667-2160 
 Telephone number: (612) 316-4305 
  
 or at such
other address, facsimile number or phone number as the specified entity most recently may have designated in writing in accordance with this paragraph to the other parties. 
  
 (h) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile shall be effective as delivery of a manually executed counterpart of this
Agreement. 
  
 (i) Interpretation. The headings of the
sections contained in this Agreement are solely for convenience or reference and shall not affect the meaning or interpretation of this Agreement. 
  
 [Signature pages follow] 
  

 13 

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the day first
written above. 
  

			
	CV THERAPEUTICS, INC.
		
	By:	 	 /s/    LOUIS G. LANGE

	 	 	 Name: Louis G. Lange M.D., Ph.D.

	 	 	 Title: Chairman and Chief Executive Officer

	
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/    MICHAEL T. LECHNER

	 	 	 Name: Michael T. Lechner

	 	 	 Title: Assistant Vice President

	
	WELLS FARGO BANK, NATIONAL ASSOCIATION, as Escrow Agent
		
	By:	 	 /s/    MICHAEL T. LECHNER

	 	 	 Name: Michael T. Lechner

	 	 	 Title: Assistant Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]